Browse by Category
Browse by Location
Search
Tag Cloud
anthrax Strategic National Stockpile Training exercise Bioterror Biomagnetics National Research Council Homeland Security Biodefense lab Army Medical Research Institute antibiotics Emergency preparedness research Bioweapons NIAID smallpox Detection technology CDC TSA Defense Dept IAEM FEMA immunization Ebola Ricin Hendra Plague treaty West Nile Camouflage Paint Marburg antidote weapons destruction Sarin VHF viruses chemical disposal dna technology prevention Robotics Technology research grants tularemia weapons control foot and mouth disease decontamination E. coli Iraq missile defenseSubscribe to our newsletter
RSS Feed
NIAID to fund development of Emergent BioSolutions' vaccine candidate
by Mary J. Lewis on November 4, 2009
W. James Jackson
ROCKVILLE, Md. — Emergent BioSolutions Inc. announced Sept. 30 that it was awarded a cooperative agreement from the National Institute of Allergy and Infectious Diseases to further the development of one of Emergent BioSolutions’ advanced anthrax vaccine candidates known as dmPA7909.
The novel vaccine candidate is designed to have the potential to confer a rapid immune response following only doses, long-term stability to enable ambient storage in the Strategic National Stockpile, and the potential to be distributed in a national emergency without the need for cold storage.
“We are excited about receiving NIAID funding support for dmPA7909, one of Emergent’s next generation anthrax vaccine candidates in development,” said W. James Jackson, senior vice president and chief scientific officer of Emergent BioSolutions.
“We look forward to advancing dmPA7909, along with our other vaccine and therapeutic candidates in our anthrax program, as we continue to support the U.S. government’s approach of funding the development of multiple medical countermeasures against the threat of bioterrorism.”
This funding of $4.9 million over two years provides for the manufacturing of clinical lots, non-clinical safety and efficacy studies, and stability studies to demonstrate whether the vaccine candidate can withstand high temperatures.
Emergent BioSolutions’ anthrax program consists of a licensed vaccine and several novel vaccines and immune-related therapeutics in development.
More News
- Soligenix announces heightened stability for RiVax
- New study shed light on how citizens will react to bio-outbreak
- Deep-UV could hold key to fighting bioattacks
- Kansas lauds proposed $40 million for biodefense facility
- Experts expect CBRN attack on U.S. within six months
- Study begins to find more effective manner of fighting smallpox
- Scott Habig joins Human Genome Sciences
- Sebelius responds to president's 2011 HHS budget
- Missile interceptor fails in mock attack
- Las Vegas expected to approve grants to fight bioterror
Read all news